{"id":1486,"date":"2024-07-12T13:40:14","date_gmt":"2024-07-12T11:40:14","guid":{"rendered":"https:\/\/semmelweis.hu\/esk\/?p=1486"},"modified":"2024-07-12T13:40:14","modified_gmt":"2024-07-12T11:40:14","slug":"covid-19-vakcina-eredmenyesseg-vizsgalata-a-60-eves-es-idosebb-europai-nepesseg-koreben-a-2022-2023-oszi-teli-idoszakban","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/esk\/2024\/07\/12\/covid-19-vakcina-eredmenyesseg-vizsgalata-a-60-eves-es-idosebb-europai-nepesseg-koreben-a-2022-2023-oszi-teli-idoszakban\/","title":{"rendered":"COVID-19 vakcina-eredm\u00e9nyess\u00e9g vizsg\u00e1lata a 60 \u00e9ves \u00e9s id\u0151sebb eur\u00f3pai n\u00e9pess\u00e9g k\u00f6r\u00e9ben a 2022-2023 \u0151szi-t\u00e9li id\u0151szakban"},"content":{"rendered":"

\"\"<\/p>\n

A leg\u00fajabb SARS-CoV-2 vari\u00e1nsok \u00e9s lesz\u00e1rmaz\u00e1si vonalak, valamint az \u00faj olt\u00f3anyagok \u00e9rt\u00e9kel\u00e9s\u00e9ben kulcsfontoss\u00e1g\u00fa a COVID-19 elleni vakcin\u00e1k eredm\u00e9nyess\u00e9g\u00e9nek (CVE) megfelel\u0151 m\u00f3don t\u00f6rt\u00e9n\u0151 monitoroz\u00e1sa, mely inform\u00e1ci\u00f3val szolg\u00e1l a jelenlegi olt\u00e1si programok sikeress\u00e9g\u00e9r\u0151l, valamint a hozz\u00e1j\u00e1rul j\u00f6v\u0151beli strat\u00e9gi\u00e1k kidolgoz\u00e1s\u00e1hoz. Tanulm\u00e1nyunk Eur\u00f3pa t\u00edz orsz\u00e1g\u00e1ban a CVE vizsg\u00e1lat\u00e1ra ir\u00e1nyul a 60 \u00e9ves vagy ann\u00e1l id\u0151sebb, h\u00e1ziorvoshoz fordul\u00f3 egy\u00e9nek k\u00f6r\u00e9ben, 2022. szeptember \u00e9s 2023. augusztus k\u00f6z\u00f6tt.<\/p>\n

A vizsg\u00e1latot teszt-negat\u00edv m\u00f3dszerrel v\u00e9gezt\u00fck. A t\u00fcnetekkel rendelkez\u0151, laborat\u00f3riumi vizsg\u00e1lattal (Rt-PCR) meger\u0151s\u00edtett SARS-COV-2 pozit\u00edv p\u00e1ciensek az eset csoportba, a negat\u00edv eredm\u00e9nnyel rendelkez\u0151k a kontroll csoportba ker\u00fcltek. Az elemz\u00e9sbe 71 \u00e9ves \u00e1tlag\u00e9letkorral 1687 esetet \u00e9s 7621 kontrollt v\u00e1logattunk be. A vizsg\u00e1lat kiterjed a COVID-19 elleni v\u00e9d\u0151olt\u00e1s \u00e1ltal ny\u00fajtott, b\u00e1rmely vari\u00e1ns, illetve specifikusan a XBB vari\u00e1ns elleni v\u00e9delem \u00e9rt\u00e9kel\u00e9s\u00e9re az olt\u00e1sban r\u00e9szes\u00fcl\u0151 csoportokban (expon\u00e1lt csoport), k\u00fcl\u00f6nb\u00f6z\u0151 referenciacsoportokkal \u00f6sszehasonl\u00edtva.<\/p>\n

Az expon\u00e1lt csoportba azok az esetek tartoztak, akik a 2022\/23-as \u0151szi\/t\u00e9li olt\u00e1si kamp\u00e1ny sor\u00e1n COVID-19 vakcin\u00e1val oltottak. A referenciacsoportba a szezon\u00e1lis CVE eset\u00e9n<\/em> a kamp\u00e1ny alatt \u00e9s az azt megel\u0151z\u0151 6 h\u00f3napban olt\u00e1sban nem r\u00e9szes\u00fcl\u0151k, m\u00edg az abszol\u00fat CVE<\/em> eset\u00e9n az olt\u00e1sban soha nem r\u00e9szes\u00fcl\u0151k tartoztak. Tov\u00e1bbi referenciacsoportk\u00e9nt defini\u00e1ltuk a relat\u00edv CVE <\/em>eset\u00e9n azokat, akik legal\u00e1bb az els\u0151dleges olt\u00e1si sorban r\u00e9szes\u00fcltek \u00e9s 6 vagy t\u00f6bb h\u00f3nappal a 22\/23 kamp\u00e1nyt megel\u0151z\u0151en kapt\u00e1k meg olt\u00e1sukat.<\/p>\n

\"\"<\/p>\n

Meghat\u00e1roztuk tov\u00e1bb\u00e1 a<\/em> m\u00e1sodik eml\u00e9keztet\u0151 olt\u00e1s relat\u00edv CVE<\/em>-\u00e9t azokn\u00e1l, akik a kamp\u00e1ny sor\u00e1n az teljes els\u0151dleges olt\u00e1si sort k\u00f6vet\u0151en a m\u00e1sodik eml\u00e9keztet\u0151 olt\u00e1st megkapt\u00e1k, \u00f6sszehasonl\u00edtva azokkal a betegekkel, akik csak egy eml\u00e9keztet\u0151 olt\u00e1st kaptak az els\u0151dleges olt\u00e1si sort k\u00f6vet\u0151en, 6 vagy t\u00f6bb h\u00f3nappal az aktu\u00e1lis olt\u00e1si kamp\u00e1nyt megel\u0151z\u0151en.<\/p>\n

Az olt\u00e1st k\u00f6vet\u0151 3 h\u00f3napon bel\u00fcl a SARS-CoV-2 v\u00edrusok elleni COVID-19 vakcina \u00f6sszes\u00edtett, becs\u00fclt eredm\u00e9nyess\u00e9ge- 29-39% volt, m\u00edg az XBB vari\u00e1nsok ellen 44% \u00e9s 52% k\u00f6z\u00f6tti, eszerint a 2022\/23-as \u0151szi\/t\u00e9li vakcin\u00e1k legal\u00e1bb 3 h\u00f3napig k\u00f6zepes szint\u0171 v\u00e9delmet ny\u00fajtanak a COVID-19 ellen. A becsl\u00e9sek szerint az eredm\u00e9nyess\u00e9g az olt\u00e1s \u00f3ta eltelt id\u0151 el\u0151rehaladt\u00e1val cs\u00f6kkent, az olt\u00e1st k\u00f6vet\u0151 6 h\u00f3nap eltelt\u00e9vel m\u00e1r nem volt kimutathat\u00f3 az olt\u00e1s okozta v\u00e9delem.<\/p>\n

\"\"<\/p>\n

A COVID-19 olt\u00e1si kamp\u00e1nyok k\u00e9pesek cs\u00f6kkenteni a SARS-CoV-2 incidenci\u00e1j\u00e1t. A szezon\u00e1lis COVID-19 vakcina eredm\u00e9nyess\u00e9get folyamatosan monitorozni kell, \u00edgy az \u00faj vakcin\u00e1k hat\u00e1soss\u00e1ga a leg\u00fajabb vari\u00e1nsokkal szemben is meghat\u00e1rozhat\u00f3 lesz.<\/p>\n

COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans<\/u><\/strong><\/span><\/h3>\n

Charlotte Laniece Delaunay, PhD<\/em> (Epiconcept),
\n<\/em>Gerg\u0151 T\u00fari, MSc <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
\n<\/em>Marine Maurel, MSc <\/em>(Epiconcept),
\n<\/em>Beatrix Oroszi, PhD <\/em>(National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest),
\n<\/em>Esther\u00a0Kissling,\u00a0MS<\/em>c <\/em>(Epiconcept)
\n<\/em>and the VEBIS Primary Care Vaccine Effectiveness Group<\/em><\/p>\n

Abstract<\/span>
\n<\/u><\/strong>Accurate monitoring of COVID-19 vaccine effectiveness (CVE) is crucial in the context of emerging SARS-CoV-2 variants\/lineages and new vaccines, to inform the ongoing vaccination programmes and contribute for future improvement strategies. In this research we aimed to evaluate the effectiveness of COVID-19 vaccines against SARS-CoV-2 infection in primary care setting across ten European countries among individuals aged 60 years and older between September 2022 and August 2023.<\/p>\n

The study was conducted using a test-negative design. Patients with symptoms and laboratory-confirmed SARS-CoV-2 were identified as cases, and those with negative test results were included in the control group. We included 1687 cases and 7621 controls with a median age of 71 years, the vaccine effectiveness is evaluated against any variants, with special focus on the XBB strain. We determined exposed groups and compared each of them to reference groups.<\/p>\n

The exposed group comprises of patients who were vaccinated against COVID-19 during the autumn\/winter campaign 2022\/23. The reference groups were: patients not vaccinated during the campaign nor in the 6 months before for seasonal CVE<\/em>, never-vaccinated patients for absolute CVE<\/em>, and patients receiving at least the primary vaccination series 6 or more months before the campaign (the precampaign cutoff) for relative CVE. We also determined the relative CVE of the second booster vaccination<\/em> in those who received the second booster vaccination during the campaign after the primary vaccination series, compared to patients with primary vaccination series receiving 1 booster dose before the precampaign cutoff.<\/p>\n

Within 3 months of vaccination, all estimates for COVID-19 vaccines against SARS-CoV-2 viruses were 29-39%, and 44% to 55% against the XBB, suggesting that the autumn\/winter 2022\/23 vaccines will provide protection against COVID-19 for at least 3 months. Effectiveness values were estimated to decrease with time since vaccination, with no protection 6 months after vaccination.<\/p>\n

COVID-19 vaccination campaigns can help to prevent a peak in SARS-CoV-2 incidence, but continued monitoring of seasonal COVID-19 vaccine effectiveness should be necessary to evaluate the efficacy of new vaccines against emerging variants.<\/p>\n

JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001\/jamanetworkopen.2024.19258. PMID: 38949812.
\nhttps:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820602<\/a><\/p>\n

K\u00e9sz\u00edtette az \"\"\u00a0<\/em><\/span><\/p>\n

RRF-2.3.1-21-2022-00006 Eg\u00e9szs\u00e9gbiztons\u00e1g Nemzeti Laborat\u00f3rium projekt <\/em><\/span>\"\"<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

A leg\u00fajabb SARS-CoV-2 vari\u00e1nsok \u00e9s lesz\u00e1rmaz\u00e1si vonalak, valamint az \u00faj olt\u00f3anyagok \u00e9rt\u00e9kel\u00e9s\u00e9ben kulcsfontoss\u00e1g\u00fa a COVID-19 elleni vakcin\u00e1k eredm\u00e9nyess\u00e9g\u00e9nek (CVE) megfelel\u0151 m\u00f3don t\u00f6rt\u00e9n\u0151 monitoroz\u00e1sa, mely inform\u00e1ci\u00f3val szolg\u00e1l a jelenlegi olt\u00e1si programok sikeress\u00e9g\u00e9r\u0151l, valamint a hozz\u00e1j\u00e1rul j\u00f6v\u0151beli strat\u00e9gi\u00e1k kidolgoz\u00e1s\u00e1hoz. Tanulm\u00e1nyunk Eur\u00f3pa t\u00edz orsz\u00e1g\u00e1ban a CVE vizsg\u00e1lat\u00e1ra ir\u00e1nyul a 60 \u00e9ves vagy ann\u00e1l id\u0151sebb, h\u00e1ziorvoshoz fordul\u00f3 egy\u00e9nek k\u00f6r\u00e9ben, …<\/p>\n","protected":false},"author":102284,"featured_media":1487,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-1486","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cikk-osszefoglalok"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/users\/102284"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/comments?post=1486"}],"version-history":[{"count":1,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1486\/revisions"}],"predecessor-version":[{"id":1490,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/posts\/1486\/revisions\/1490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media\/1487"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/media?parent=1486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/categories?post=1486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/esk\/wp-json\/wp\/v2\/tags?post=1486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}